In a nutshell This study investigated the risk of pelvic fracture (PF) in patients with rectal cancer who received radiation therapy. Researchers suggested that there is an increased risk of PF in these patients. Some background Rectal cancer rates have been increasing, especially in younger populations. Due to improvements in medical care, survival...
Read MoreIn a nutshell This phase 3 trial will investigate the safety and effectiveness of osimertinib (Tagrisso) after chemoradiation (CR) in non-small cell lung cancer (NSCLC). The main outcome will be progression-free survival (PFS; survival without cancer growing or spreading). The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreIn a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...
Read More
In a nutshell This study examined how long hormonal therapy should continue in patients who have received radiotherapy after prostate removal surgery (prostatectomy). This study concluded that patients with a higher number of risk risk factors should receive HT for a longer period of time. Some background Radical prostatectomy (RP) is...
Read More
In a nutshell This study evaluated the outcomes of active surveillance versus upfront treatment for patients with nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL). It was found that active surveillance is effective for managing NLPHL. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma. It may be treated with intensive...
Read More
In a nutshell This study wanted to look at the effect of low growth hormone (GH) on the behavior and function of adults who had acute lymphoblastic leukemia (ALL) as children. Researchers concluded that therapy for ALL may cause low GH. They also suggest that behavioral function may be affected by treatment and not by low GH. Some...
Read MoreIn a nutshell This trial is comparing the effectiveness of a new therapy, bb2121, to commonly used combinations of drugs for relapsing/refractory (unresponsive) multiple myeloma (RRMM). The main outcome to be measured is the time from the start of treatment until cancer worsens. The details Many patients are cured with standard treatments, such as...
Read More
In a nutshell This study reviewed how the research on pediatric and adult Hodgkin lymphoma (HL) could be applied to adolescent HL. The main finding was that treatments for pediatric and adult HL have similar effects in adolescent HL. Some background About 8500 people are diagnosed with HL in the US each year. There are 2 main types of HL:...
Read More
In a nutshell This study investigated the effects of blood cell transfer in patients with human immunodeficiency virus (HIV) who had developed lymphomas. At 4 years, it was found that 70% of patients survived following blood cell transfer. Some background Lymphomas are forms of cancer which affect the blood cells. Two common types of lymphoma are...
Read More
In a nutshell This article investigated the safety and effectiveness of durvalumab (Imfinzi) for the treatment of unresectable non-small-cell lung cancer (NSCLC). The authors concluded that durvalumab is safe and can improve survival of these patients. Some background Non-small cell lung cancer (NSCLC) is the most common kind of lung cancer....
Read More
In a nutshell This study evaluated the safety and effectiveness of ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that ibritumomab tiuxetan...
Read More
In a nutshell This study evaluated the effectiveness and safety of venetoclax (Venclexta) monotherapy (single-agent treatment) in patients with relapsed (cancer recurrence) or refractory (does not respond to initial treatment) mantle cell lymphoma (MCL). This study concluded that venetoclax monotherapy is promising, with minimal side effects. Some...
Read More
